April 9, 2024

Novel Risk Factors for Predicting Immune-effector Cell Associated Neurotoxicity Syndrome (ICANS) (P3-14.001)

Key Points

Key points are not available for this paper at this time.

Abstract

To characterize novel risk factors for the development of ICANS after treatment with chimeric antigen receptor (CAR)-T Cell therapy for management of cancer.

اسأل الذكاء الاصطناعي

Bookmark

اسأل الذكاء الاصطناعي

Bookmark

Cite This Study

Friedman et al. (Tue,) studied this question.

synapsesocial.com/papers/68e6fdadb6db643587677c8a https://doi.org/https://doi.org/10.1212/wnl.0000000000204489

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Immune effector cell-associated neurotoxicity syndrome: integrative mechanisms, predictive biomarkers, and translational pathways for prevention in CAR T-cell therapy2026 · 1 citations
2Risk stratification for immune effector cell-associated neurotoxicity syndrome in patients receiving chimeric antigen receptor T cell therapy.2024 · 2 citations
3CAR+ extracellular vesicles predict ICANS in patients with B cell lymphomas treated with CD19-directed CAR T cells2024 · 25 citations
4Novel Treatment Modality for Chimeric Antigen Receptor T-cell Therapy Complications: A Case Report2024
5Autonomic dysfunction as manifestation of ICANS: A case report2024 · 4 citations